Dr. Sagar Uday Nigwekar, MD

Dr. Nigwekar practices at Fresenius Kidney Care Chelsea in Norfolk, Massachusetts.

Dr. Nigwekar's NPI, 1710939848, was assigned on May 17, 2006. Dr. Nigwekar holds Massachusetts license 252311.

Dr. Nigwekar's primary practice is Fresenius Kidney Care Chelsea, at 31 Pine St, Norfolk, MA 02056 in Norfolk County. The practice phone is (617) 887-9284.

Dr. Nigwekar's primary practice is Fresenius Kidney Care Chelsea in Norfolk, Massachusetts. Dr. Nigwekar is also affiliated with Massachusetts General Hospital. The medical group on file is Commonwealth Nephrology Associates. Dmand AI also links Dr. Nigwekar to 3 more hospitals, 4 group practices and clinics, 4 medical groups and 1 dialysis center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nigwekar practices, 9 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Nigwekar's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dmand AI has Dr. Nigwekar's licenses on file in 2 states: Massachusetts and New York.

CMS data shows 706 Medicare services from Dr. Nigwekar across 9 procedure codes in 2024, for 239 Medicare patients. Medicare paid $65,100 for them.

CMS counts 239 Medicare patients who saw Dr. Nigwekar in 2024. The largest group is 75 to 84, with 100 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 33% are also on Medicaid. Their average risk score is 3.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nigwekar's median patient age at 74, with 50% women.

In 2024, Dr. Nigwekar wrote 367 Medicare Part D claims for 73 patients. 81% of them were for generic drugs. CMS names the drug for 185 of them, across 10 drugs with 11 or more claims each, at $84,480 in total drug cost. In 2023, CMS named 186 claims across 10 drugs.

Dr. Nigwekar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nigwekar as offering telehealth.

Dmand AI links 117 papers to Dr. Nigwekar, published from 2009 to 2025. 2019 was the busiest year, with 10. The most frequent topics are Calciphylaxis, Kidney Failure, Chronic and Renal Dialysis. Dr. Nigwekar has published most often in Clin J Am Soc Nephrol. Dr. Nigwekar's most frequent co-authors are Ravi Ishwar Thadhani, MD, MPH, Andrew S. Allegretti, MD and Rosalynn M. Nazarian, MD.

Dmand AI links Dr. Nigwekar to 1 clinical trial. Conditions studied include Kidney Failure, Chronic and Atrial Fibrillation.

CMS Open Payments shows 88 general payments to Dr. Nigwekar from 15 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 54% of the total. Fresenius USA Marketing, Inc. paid the most, $25,633.